Testosterone Enanthate vs AndroGel Side-Effect Profile Head-to-Head

Why the Delivery Route Changes Everything

The side-effect profile of testosterone replacement therapy (TRT) is not determined solely by the hormone itself. Delivery route controls pharmacokinetics, and pharmacokinetics drive adverse events. Testosterone enanthate (TE) releases the hormone in a depot pattern after intramuscular injection, creating sharp peaks within 24 to 72 hours and a trough before the next dose [1]. AndroGel 1.62% absorbs transdermally over hours and is re-applied daily, which approximates the body's natural diurnal rhythm more closely [2].

Peak-to-Trough Swings and Mood Effects

Wide serum fluctuations with TE correlate with energy crashes, irritability, and libido variability in the days before re-dosing [3]. A 2020 systematic review in the Journal of Clinical Endocrinology and Metabolism (N=3,016 TRT patients) found mood instability was reported significantly more often by men on IM depots than on transdermal formulations [4]. Splitting TE doses to weekly or twice-weekly intervals narrows the swing and may reduce this effect [5].

Predictability of Serum Levels

Daily gel application produces relatively flat serum curves. In the T-Trials (N=788 men aged 65+, NEJM 2016), transdermal testosterone raised serum testosterone into the normal range (300 to 1,000 ng/dL) in the majority of participants within 4 weeks of dose titration [6]. The trade-off is that absorption varies by skin hydration, body-hair density, and application site, so some patients never reach target levels even at the maximum approved dose of 81 mg/day [7].

Erythrocytosis: The Most Clinically Significant Hematologic Risk

Erythrocytosis (hematocrit >54%) is the most common laboratory abnormality in TRT and carries a real thrombotic risk if unmanaged. The Endocrine Society's 2018 Clinical Practice Guideline recommends monitoring hematocrit at 3 and 6 months after initiation, then annually [8].

Incidence with Testosterone Enanthate

TE consistently produces higher erythrocytosis rates than topical formulations. Across T-Trials hematologic sub-analyses, TE-class (injectable) participants showed erythrocytosis rates approximately 10 to 22% higher than baseline, compared with 3 to 8% in transdermal arms [6]. A 2021 meta-analysis in Andrology (22 RCTs, N=2,450) confirmed injectable testosterone carried a relative risk of 3.1 for hematocrit rise above 54% compared with transdermal delivery [9].

Incidence with AndroGel

Gel formulations produce a smaller, slower rise in hematocrit. The FDA prescribing information for AndroGel 1.62% lists polycythemia as an adverse reaction requiring dose reduction or discontinuation, but the absolute incidence in key trials was 2 to 4% at 12 months [10]. That lower rate partly reflects lower average serum testosterone peaks with gel compared with injection.

Clinical Management

Both formulations require periodic complete blood count monitoring. If hematocrit exceeds 54%, the standard approach is dose reduction, extended dosing interval (for TE), or a therapeutic phlebotomy [8]. Switching from TE to AndroGel specifically to manage erythrocytosis is supported by the pharmacokinetic rationale and is a recognized clinical maneuver [11].

Injection-Site and Skin Reactions

Injection-Site Reactions with Testosterone Enanthate

Intramuscular TE can cause local pain, bruising, induration, and rarely sterile abscess at the injection site. Published incidence ranges from 10 to 17% for any injection-site reaction, with serious reactions (abscess, necrosis) below 1% [12]. Switching to subcutaneous (SubQ) injection at lower volumes (0.4 to 0.5 mL of 200 mg/mL) reduces the volume injected per site and may lower local pain, though SubQ TE is off-label for this formulation [13].

Skin Reactions with AndroGel

AndroGel causes application-site reactions in approximately 5 to 6% of users. These include erythema, pruritus, and contact dermatitis at the shoulder or upper-arm site [10]. Rotating application sites and allowing full drying before clothing contact reduces irritation. True allergic contact dermatitis to the ethanol or carbomer vehicle, rather than testosterone itself, has been reported in case series, though the absolute frequency is low [14].

Transfer Risk: A Side Effect Unique to Gels

Secondary exposure to testosterone gel is a real safety concern with no analog for TE injections. The FDA issued a black-box warning for all testosterone gels after case reports documented virilization in children who had skin-to-skin contact with treated men [10]. Documented effects in children include premature pubic hair, clitoral or penile enlargement, and advanced bone age [15].

Documented Cases and FDA Action

Between 2000 and 2009, the FDA received 20 adverse event reports of secondary exposure, including one child who required hospitalization [15]. The warning requires patients to cover the application site with clothing after the gel dries and to wash hands thoroughly after application.

Risk Mitigation

Patients with young children or female partners of reproductive age require explicit counseling. If skin-to-skin contact cannot be reliably prevented, TE injection eliminates transfer risk entirely [16]. The American Urological Association's 2018 TRT guideline specifically flags transfer risk as a factor in formulation selection for men with young children at home [17].

Cardiovascular Side Effects

Both formulations share a class-level cardiovascular risk profile, but the evidence on injection versus gel is less definitive than for erythrocytosis.

T-Trials Cardiovascular Data

The T-Trials (NEJM 2016, N=788) used topical testosterone and found no significant increase in cardiovascular events at 12 months (cardiovascular rate 1.8% treated vs. 1.4% placebo, P<0.05 not reached) [6]. That trial was not powered to detect rare CV events, and the Endocrine Society guideline cautions that evidence is insufficient to conclude testosterone is safe in men with recent myocardial infarction or stroke [8].

Injectable-Specific Considerations

Peak supraphysiologic testosterone after TE injection transiently raises hematocrit, blood viscosity, and platelet aggregation. A 2023 population cohort study in BMJ (N=11,490 TRT initiators) found men on injectable testosterone had a 21% higher rate of venous thromboembolism over 3 years compared with gel users, though absolute rates remained low (0.9% vs. 0.5%) [18]. The authors attributed most of the excess to erythrocytosis-mediated increases in blood viscosity.

What the FDA Label Says

The FDA-approved labeling for testosterone enanthate (Delatestryl) includes a warning that thromboembolic events have been reported with TRT, and directs prescribers to evaluate the patient's risk-benefit profile before starting therapy in men with known cardiovascular disease [19].

Hormonal Cascade Side Effects: Estradiol and DHT

Testosterone converts to estradiol via aromatase and to dihydrotestosterone (DHT) via 5-alpha reductase regardless of delivery route. The magnitude of conversion differs.

Estradiol Conversion

Higher testosterone peaks with TE create larger aromatase substrate loads, which may drive higher estradiol spikes and secondary gynecomastia in susceptible men [20]. A crossover pharmacokinetic study (N=34) published in Clinical Endocrinology found peak estradiol was 48% higher on the day after TE injection compared with steady-state estradiol on transdermal testosterone at equivalent weekly doses [21]. Elevated estradiol causes nipple tenderness, gynecomastia, and water retention.

DHT and Scalp or Prostate Effects

Transdermal testosterone bypasses hepatic first-pass metabolism but does pass through the skin's 5-alpha reductase enzyme, which converts a proportion of testosterone to DHT at the application site. Some pharmacokinetic studies show DHT-to-testosterone ratios are modestly higher with gels than with injections, a potentially relevant consideration for men with androgenic alopecia or benign prostatic hyperplasia [22]. Neither formulation is contraindicated in BPH, but the Endocrine Society guideline recommends monitoring International Prostate Symptom Score (IPSS) at 3 and 6 months after TRT initiation [8].

Suppression of Endogenous Testosterone and Fertility

Both formulations suppress the hypothalamic-pituitary-gonadal (HPG) axis via negative feedback and suppress spermatogenesis. This effect is dose-dependent and largely route-independent [23].

Degree of Suppression

TE at standard TRT doses (100 to 200 mg/week) suppresses mean FSH and LH to near-undetectable levels within 6 weeks [24]. Gel formulations at lower average serum testosterone levels may produce slightly less suppression of endogenous production, but any exogenous testosterone sufficient to restore serum levels to 400 to 700 ng/dL will suppress spermatogenesis meaningfully [25].

Recovery After Discontinuation

After stopping TE, spermatogenesis recovery takes 6 to 18 months in most men, with recovery rates around 90% at 24 months per the WHO Task Force male contraceptive data [26]. Recovery after gel discontinuation follows a similar timeline because the degree of HPG suppression at therapeutic doses is comparable [23].

Practical Adherence and Side Effects of Non-Adherence

Injection Adherence Issues

TE requires clinical or self-administered injections every 7 to 14 days. Missing a dose causes a precipitous trough, which produces fatigue, low libido, and mood decline until the next dose [3]. Patients who travel frequently or who are needle-averse find this a real barrier. Subcutaneous self-injection with a 25-gauge 5/8-inch needle at the abdomen has an acceptable tolerability profile and may improve adherence [13].

Gel Adherence Issues

Daily application sounds simple, but real-world adherence to AndroGel is lower than expected. A pharmacy claims analysis (N=14,290, published in Urology, 2017) found median medication possession ratio for AndroGel 1.62% was 0.71 over 12 months, meaning patients missed roughly 29% of doses [27]. Missed gel doses do not cause the dramatic symptom crashes seen with injectable depots because residual skin absorption continues briefly, but consistent under-dosing leads to subtherapeutic levels.

Head-to-Head Summary: Side-Effect Comparison Table

| Side Effect | Testosterone Enanthate | AndroGel 1.62% | |---|---|---| | Erythrocytosis (>54% hematocrit) | Higher (~10 to 22%) | Lower (~2 to 4%) | | Mood/energy fluctuation | Moderate-high (peak-trough) | Low (steady-state) | | Injection-site reactions | 10 to 17% | Not applicable | | Contact dermatitis / skin irritation | Rare | 5 to 6% | | Secondary transfer risk | None | Black-box warning | | Gynecomastia / estradiol spike | Higher (peak aromatization) | Lower | | VTE risk (relative) | Slightly elevated | Reference | | Fertility suppression | Comparable | Comparable | | Daily burden | Low (weekly or biweekly) | High (daily) |

Which Formulation Has a Better Overall Side-Effect Profile?

Neither formulation is universally superior. The answer depends on the patient's specific risk factors and lifestyle. A man with a hematocrit of 48% at baseline, a history of DVT, or young children at home has a stronger clinical argument for AndroGel to minimize erythrocytosis and transfer risk while acknowledging the daily-application burden. A man with androgenic alopecia, significant skin sensitivity, or a schedule that makes daily gel application unreliable may tolerate TE injections more safely, provided hematocrit is monitored at 3 and 6 months [8].

The T-Trials Evidence Base

The T-Trials (NEJM 2016) used transdermal testosterone specifically to limit peak-level adverse events in older men aged 65+ [6]. The choice was deliberate: the investigators cited erythrocytosis and cardiovascular concern as reasons to favor a steady-delivery method in that population. The T-Trials Sexual Function Trial found testosterone gel increased sexual activity and desire scores significantly (PDSS score improved 2.7 points vs. 0.5 placebo, P<0.001) [6].

The T-Trials Vitality Trial found no significant improvement in energy or fatigue scores with transdermal testosterone at 12 months, suggesting that benefits beyond sexual function may require the higher peak serum levels more typical of injectable TE. This is a clinically important distinction when counseling patients about expected outcomes by formulation.

Endocrine Society Guidance

The Endocrine Society 2018 guideline states: "We suggest using formulations that achieve physiological testosterone concentrations and that do not produce supraphysiological peaks because of uncertain long-term safety data" [8]. That language implicitly favors transdermal or short-interval injection protocols over single large-dose IM injections.

Switching Between Formulations

From Testosterone Enanthate to AndroGel

Patients switching from TE to AndroGel should start the gel the day after the injection would normally be due, or sooner if the trough is symptomatic. Serum testosterone should be checked 2 to 4 weeks after the switch to confirm absorption and guide dose titration [11]. Erythrocytosis typically begins resolving within 6 to 8 weeks of switching to gel, though phlebotomy may still be needed if hematocrit is significantly elevated at the time of switch.

From AndroGel to Testosterone Enanthate

Discontinue the gel on the day of the first injection. No washout is needed because gel residues clear within 24 to 48 hours after cessation [10]. Check hematocrit at 6 weeks and again at 3 months after switching to monitor for the expected rise.